Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation: An Early Remission Induction Study
Applying a treat-to-target approach in treatment-naïve early axSpA allows to induce high rates of sustained clinical remission, regardless of the presence of microscopic gut inflammation.
Authors
- Triana Lobatón (ORCID: https://orcid.org/0000-0003-1817-7704)
- Anne Hoorens (ORCID: https://orcid.org/0000-0002-0736-2034)
- Ann‐Sophie De Craemer (ORCID: https://orcid.org/0000-0001-7062-8934)
- Liselotte Deroo (ORCID: https://orcid.org/0000-0001-7954-9044)
- Manouk de Hooge (ORCID: https://orcid.org/0000-0002-0652-9808)
- Gaëlle Varkas (ORCID: https://orcid.org/0000-0001-7606-9256)
- Filip Van den Bosch (ORCID: https://orcid.org/0000-0002-3561-5932)
- Zuzanna Łukasik (ORCID: https://orcid.org/0000-0001-9551-3578)
- Thomas Renson (ORCID: https://orcid.org/0000-0002-5503-000X)
- Philippe Carron (ORCID: https://orcid.org/0000-0001-9254-6171)
- Dirk Sw Elewaut (ORCID: https://orcid.org/0000-0002-7468-974X)
- Claude Cuvelier
- Jan Lenaerts
Institutions
- Flanders Marine Institute (BE)
- Ghent University Hospital (BE)
- Jessa Hospital (BE)
- VIB-UGent Center for Inflammation Research (BE)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1002/art.43283
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00